Abstract:
I. Introduction
Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir combined dosage form is used for the treatment of HIV-1infection in adult patients 1 . Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine is 5-fluoro-1-[(2R, 5S)-2-(hydroxyl methyl)-1, 3-oxathiolan-5-yl] cytosine were shown in figure 1A . Emtricitabine 5'-triphosphate inhibits the activity of the HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA which results in chain termination. Emtricitabine 5′-triphosphate is a weak inhibitor of mammalian DNA polymerases α, β, ε, and mitochondrial DNA polymerase γ. Tenofovir Disoproxil Fumarate is a fumaric acid salt of the bis iso propoxy carbonyl oxy methyl ester derivative of tenofovir. Tenofovir Disoproxil Fumarate figure 1C . Cobicistat is a selective, mechanism-based inhibitor of cytochromes P450 of the CYP3A subfamily. Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as elvitegravir, where bioavailability is limited and half-life is shortened by CYP3A-dependent metabolism. Elvitegravir is 6-(3-Chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4dihydro quinoline-3-carboxylic acid were shown in figure 1D . Elvitegravir inhibits the strand transfer activity of HIV-1 integrase (integrase strand transfer inhibitor; INSTI), an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the viral infection. Elvitegravir does not inhibit human topoisomerases I or II Literature survey reveals that many analytical methods are reported for determination of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir individually and with other combinations which includes high performance liquid chromatography (HPLC) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , liquid chromatography-mass spectrophotometry (LC-MS) 19, 20 , UV-Spectrophotometry 21 and high performance thin layer chromatography (HPTLC) 22 methods. However, no method is reported for simultaneous estimation of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir in combined dosage form by Reversed Phase Ultra Performance Liquid Chromatography (UPLC) with forced degradation studies. The present study was aimed to develop a novel and validated Reversed Phase Ultra Performance Liquid Chromatography (UPLC) method for the simultaneous estimation of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir in bulk and pharmaceutical dosage form with forced degradation studies according to ICH guidelines 23 .
Instrumentation
The analysis was performed by using a chromatographic system from Waters Acquity UPLC system with PDA detector. The UPLC system was equipped with Empower 2 software. Semi-micro analytical balance (India), Ultrasonic bath sonicator (Frontline FS 4, Mumbai, India), Digital pH meter (Systronics model 802) and Whatmann filter paper No. 41 (Whatmann International Ltd., England) were used in the study.
Selection of wavelength
In simultaneous estimation of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir isosbestic wavelength is used. Standard stock solutions of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir were prepared by dissolving 200 mg of Emtricitabine, 300 mg of Tenofovir Disoproxil Fumarate, 150 mg of Cobicistat and 150 mg of Elvitegravir in 100 ml of diluent into a 100 ml clean dry volumetric flask and the standard solutions was filtered through 0.45 μm nylon membrane filter and degassed by sonicator to get the concentration of 2000 µg/mL of Emtricitabine, 3000 µg/mL of Tenofovir Disoproxil Fumarate, 1500 µg/mL of Cobicistat and 1500 µg/mL of Elvitegravir. From the above standard stock solution of 2000 µg/mL of Emtricitabine, 3000 µg/mL of Tenofovir Disoproxil Fumarate, 1500 µg/mL of Cobicistat and 1500 µg/mL of Elvitegravir further pipette 1 mL and transferred into a 100 mL volumetric flask and dilute up to the mark with diluent to get the concentration of 20 µg/mL of Emtricitabine, 30 µg/mL of Tenofovir Disoproxil Fumarate, 15 µg/mL of Cobicistat and 15 µg/mL of Elvitegravir. The wavelength of maximum absorption (λmax) of 20 µg/mL of Emtricitabine, 30 µg/mL of Tenofovir Disoproxil Fumarate, 15 µg/mL of Cobicistat and 15 µg/mL of Elvitegravir were scanned using UV-Visible spectrophotometer within the wavelength region of 200-400 nm against mobile phase as blank. The isosbestic wavelength (λmax) was found to be 268 nm for the combination shown in figure 2. 
Chromatographic conditions
Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir were analyzed in ACQUITY UPLC BEH C 18 (100 mm×2.1 mm, 1.7 m particle size) column for the chromatographic separation. The mobile phase was composed of 0.01M Ammonium acetate (pH adjusted to 7.5 with ammonium hydroxide) and Acetonitrile (45:55, v/v). Filtered through 0.45µm nylon membrane filter under vacuum filtration and pumped at ambient temperature, at a flow rate of 0.25 mL/min with UV detection wavelength at 268 nm. Injection volume was 20μL. From the above standard stock solution of 2000 µg/mL of Emtricitabine, 3000 µg/mL of Tenofovir Disoproxil Fumarate, 1500 µg/mL of Cobicistat and 1500 µg/mL of Elvitegravir further pipette 3 mL and transferred into a 100 mL volumetric flask and dilute up to the mark with diluent to get the concentration of 60 µg/mL of Emtricitabine, 90 µg/mL of Tenofovir Disoproxil Fumarate, 45 µg/mL of Cobicistat and 45 µg/mL of Elvitegravir.
Preparation of sample solutions of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir
Stribild (Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir) contains equivalent amount of 200 mg of Emtricitabine, 300 mg of Tenofovir Disoproxil Fumarate, 150 mg of Cobicistat and 150 mg of Elvitegravir were taken into 100 mL clean dry volumetric flask, diluent was added and sonicated to dissolve it completely and was filtered through 0.45 μm nylon membrane filter and volume was made up to the mark with the same diluent. Further pipette out 3 mL from the above Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir sample stock solution into a 100 mL volumetric flask and diluted up to the mark with diluent to get the concentration of 60 µg/mL of Emtricitabine, 90 µg/mL of Tenofovir Disoproxil Fumarate, 45 µg/mL of Cobicistat and 45 µg/mL of Elvitegravir. 20 L from standard and sample solution were injected into the chromatographic system and the peak areas were measured for Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir which was shown in figure 3 and 4 and the assay % was calculated by comparing the peak area of standard and sample chromatogram by using the formula given below and the assay results was shown in Table 1 .
Label Claim Where: AT = Average peak area of sample preparation AS= Average peak area of standard preparation WS = Weight of standard taken in mg WT=Weight of sample taken in mg P = Percentage purity of working standard DS= Dilution factor for standard preparation DT=Dilution factor for sample preparation DOI: 10.9790/3008-1104024969 www.iosrjournals.org 
Method validation
The developed method for the simultaneous estimation of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir was validated as per the ICH guidelines for the parameters like system suitability, specificity, linearity, accuracy, precision, ruggedness, robustness, limit of detection (LOD) and limit of quantitation (LOQ) 23 .
II. Results

UPLC method development
To optimize the UPLC parameters, a number of commercially available UPLC columns and various mobile phases were evaluated for its chromatographic behavior of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir. A satisfactory separation and good peak symmetry for Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir were obtained with ACQUITY UPLC BEH C 18 (100 mm×2.1 mm, 1.7 m particle size) column, Waters ACQUITY UPLC system with PDA detector and mobile phase contained a mixture of 0.01 M Ammonium acetate buffer (pH adjusted to 7.5 with ammonium hydroxide) and Acetonitrile (45:55, v/v) was delivered at a flow rate of 0.25 mL/min to get better reproducibility and repeatability. Quantification was achieved with PDA detection at 268 nm based on peak area.
UPLC method validation 3.2.1 System suitability
At first the UPLC system was optimized as per the chromatographic conditions. One blank followed by six replicates of a single calibration standard solution of 60 µg/mL of Emtricitabine, 90 µg/mL of Tenofovir Disoproxil Fumarate, 45 µg/mL of Cobicistat and 45 µg/mL of Elvitegravir was injected to check the system suitability. To ascertain the system suitability for the proposed method, the parameters such as retention time, theoretical plates, peak asymmetry and resolution were taken and results were presented in 
Specificity
The effect of excipients and other additives usually present in the combined dosage form of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir in the determination under optimum conditions was investigated. The specificity of the UPLC method was established by injecting the blank and placebo solution into the UPLC system. The representative chromatogram of blank and placebo was shown in figure 5 and 6. were taken into 100 mL clean dry volumetric flask, diluent was added and sonicated to dissolve it completely and was filtered through 0.45 μm nylon membrane filter and volume was made up to the mark with the same diluent. Further pipette out 0.2 mL from the above Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir sample stock solution into a 10 mL volumetric flask and diluted up to the mark with diluent to get the concentration of 40 µg/mL of Emtricitabine, 60 µg/mL of Tenofovir Disoproxil Fumarate, 30 µg/mL of Cobicistat and 30 µg/mL of Elvitegravir.
Preparation of standard solution of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir for accuracy studies
Standard stock solutions of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir were prepared by dissolving 200 mg of Emtricitabine, 300 mg of Tenofovir Disoproxil Fumarate, 150 mg of Cobicistat and 150 mg of Elvitegravir in 100 mL of diluent into a 100 mL clean dry volumetric flask and the standard solutions was filtered through 0.45 μm nylon membrane filter and degassed by sonicator to get the concentration of 2000 µg/mL of Emtricitabine, 3000 µg/mL of Tenofovir Disoproxil Fumarate, 1500 µg/mL of Cobicistat and 1500 µg/mL of Elvitegravir.
a.) Preparation of 50% standard solution
From the standard stock solution of 2000 µg/mL of Emtricitabine, 3000 µg/mL of Tenofovir Disoproxil Fumarate, 1500 µg/mL of Cobicistat and 1500 µg/mL of Elvitegravir further pipette 0.1 mL and transferred into a 10 mL volumetric flask and dilute up to the mark with diluent to get the concentration of 20 µg/mL of Emtricitabine, 30 µg/mL of Tenofovir Disoproxil Fumarate, 15 µg/mL of Cobicistat and 15 µg/mL of Elvitegravir.
b.) Preparation of 100% standard solution
From the standard stock solution of 2000 µg/mL of Emtricitabine, 3000 µg/mL of Tenofovir Disoproxil Fumarate, 1500 µg/mL of Cobicistat and 1500 µg/mL of Elvitegravir further pipette 0.2 mL and transferred into a 10 mL volumetric flask and dilute up to the mark with diluent to get the concentration of 40 µg/mL of Emtricitabine, 60 µg/mL of Tenofovir Disoproxil Fumarate, 30 µg/mL of Cobicistat and 30 µg/mL of Elvitegravir.
c.) Preparation of 150% standard solution
From the standard stock solution of 2000 µg/mL of Emtricitabine, 3000 µg/mL of Tenofovir Disoproxil Fumarate, 1500 µg/mL of Cobicistat and 1500 µg/mL of Elvitegravir further pipette 0.3 mL and transferred into a 10 mL volumetric flask and dilute up to the mark with diluent to get the concentration of 60 µg/mL of Emtricitabine, 90 µg/mL of Tenofovir Disoproxil Fumarate, 45 µg/mL of Cobicistat and 45 µg/mL of Elvitegravir. Acceptance Criteria: The Recovery % for each level should be between 98.0 to 102.0%. were taken into 100 mL clean dry volumetric flask, diluent was added and sonicated to dissolve it completely and was filtered through 0.45 μm nylon membrane filter and volume was made up to the mark with the same diluent. Further pipette out 3 mL from the above Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir sample stock solution into a 100 mL volumetric flask and diluted up to the mark with diluent to get the concentration of 60 µg/mL of Emtricitabine, 90 µg/mL of Tenofovir Disoproxil Fumarate, 45 µg/mL of Cobicistat and 45 µg/mL of Elvitegravir. A homogenous sample of a single batch is analyzed six times and was checked whether the method is giving consistent results. The RSD % for the assay of six replicate injections was calculated as mentioned in Table 5 . Acceptance Criteria: The RSD % for the assay of six sample injections should not be more than 2%. Table 6 . Acceptance Criteria: The RSD % for the peak area of six standard injections should not be more than 2%. 
Intermediate precision/ruggedness
The intermediate precision (also known as Ruggedness) of the method was evaluated by performing precision on different laboratories by different analysts and different days. The sample preparation concentration of 60 µg/mL of Emtricitabine, 90 µg/mL of Tenofovir Disoproxil Fumarate, 45 µg/mL of Cobicistat and 45 µg/mL of Elvitegravir was injected six times into the UPLC system and the RSD % for the assay of six replicate injections was calculated as mentioned in Table 7 and 8. Acceptance Criteria: The RSD % for the assay of six sample injections should not be more than 2%. 
Limit of Detection (LOD) and Limit of Quantification (LOQ)
Limit of Detection (LOD) and Limit of Quantification (LOQ) were calculated as 3.3×SD/S and 10×SD/S respectively as per ICH guidelines, Where SD is the standard deviation of the response (Y-intercept) and S is the slope of the calibration curve. The LOD is the smallest concentration of the analyte that gives a measurable response (signal to noise ratio of 3). The LOD of Emtricitabine, Tenofovir Disoproxil Fumarate, DOI: 10.9790/3008-1104024969 www.iosrjournals.org 60 | Page
Cobicistat and Elvitegravir was calculated and shown in Table 9 . The LOQ is the smallest concentration of the analyte which gives response that can be accurately quantified (signal to noise ratio of 10). The LOQ of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir was calculated and shown in Table 9 . 
Robustness
As part of the Robustness, deliberate change in the flow rate and mobile phase proportion was made to evaluate the impact on the method. The results reveal that the method is robust. The results are summarized in Table 10 and 11. 
Stability of solution
The RSD % of the assay of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir from the solution stability and mobile phase stability experiments was within 2%. The results of the solution and mobile phase stability experiments confirm that the sample solutions and mobile phase used during the assays were stable upto 48 hours at room temperature was calculated and shown in Table 12 . 
Alkali Degradation Studies
To 1 mL of stock solution of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir, 1 mL of 2 N sodium hydroxide was added and refluxed for 30 mins at 60 0 C. The resultant solution was diluted to obtain 60 µg/mL of Emtricitabine, 90 µg/mL of Tenofovir Disoproxil Fumarate, 45 µg/mL of Cobicistat and 45 µg/mL of Elvitegravir solution and 20 µL solutions were injected into the UPLC system and the chromatogram were recorded to assess the stability of sample was shown in figure 10 and purity plot of alkali degradation for Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir was shown in figure 11. 
Oxidative degradation Studies
To 1 mL of stock solution of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir, 1 mL of 3 % Hydrogen peroxide (H 2 O 2 ) was added and the solution was kept for 30 mins at 60 0 C. For UPLC study, the resultant solution was diluted to obtain 60 µg/mL of Emtricitabine, 90 µg/mL of Tenofovir Disoproxil Fumarate, 45 µg/mL of Cobicistat and 45 µg/mL of Elvitegravir solution and 20 µL solutions were injected into the UPLC system and the chromatogram were recorded to assess the stability of sample was shown in figure 12 and purity plot of oxidative degradation for Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir was shown in figure 13. 
Photol y t i c d e g r a d a t i o n studies
The photochemical stability of the drug was also studied by exposing the drug solution to UV light by keeping the beaker in UV Chamber for 7 days or 200 Watt hours/m 2 in photo stability chamber. For UPLC study, the resultant solution was diluted to obtain 60 µg/mL of Emtricitabine, 90 µg/mL of Tenofovir Disoproxil Fumarate, 45 µg/mL of Cobicistat and 45 µg/mL of Elvitegravir solution and 20 µL solutions were injected into the UPLC system and the chromatogram were recorded to assess the stability of sample was shown in figure 14 and purity plot of photolytic degradation for Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir was shown in figure 15. 
Thermal Degradation Studies
The standard drug solution w a s placed in a n oven at 105 0 C for 6 hrs to study dry heat degradation. For UPLC study, the resultant solution was diluted to 60 µg/mL of Emtricitabine, 90 µg/mL of Tenofovir Disoproxil Fumarate, 45 µg/mL of Cobicistat and 45 µg/mL of Elvitegravir solution and 20 µL solutions were injected into the UPLC system and the chromatogram were recorded to assess the stability of sample was shown in figure 16 and purity plot of thermal degradation for Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir was shown in figure 17. 
III. Discussion
This method was intended for rapid estimation of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir in bulk and pharmaceutical dosage form. Good separation of the chromatographic peaks was observed and no interfering peaks are found. A number of commercially available UPLC columns and various mobile phases were evaluated for its chromatographic behavior of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir. The best response were obtained with ACQUITY UPLC BEH C 18 (100 mm×2.1 mm, 1.7 m particle size) column, Waters ACQUITY UPLC system with PDA detector and mobile phase contained a mixture of 0.01 M Ammonium acetate buffer (pH adjusted to 7.5 with ammonium hydroxide) and Acetonitrile (45:55, v/v) was delivered at a flow rate of 0.25 mL/min. Quantification was achieved with PDA detection at 268 nm based on peak area. Fumarate, Cobicistat and Elvitegravir respectively, reveal that the proposed method is precise. LOD values for Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir were found to be 0.14 µg/mL, 0.45 µg/mL, 0.37 µg/mL and 0.25 µg/mL respectively and LOQ values for Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir were found to be 0.44 µg/mL, 1.36 µg/mL, 1.12 µg/mL and 0.76 µg/mL respectively. The RSD % values of robustness studies were found to be < 2% reveal that the method is robust enough. These data show that the proposed method is accurate and precise for the determination of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir in its bulk and pharmaceutical dosage form.
IV. Conclusion
The present RP-UPLC-DAD method for simultaneous estimation of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir in their combine dosage form was established and validated as per the ICH guidelines. Linearity was achieved for Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir in the range of 20-100 µg/mL for Emtricitabine, 30-150 µg/mL for Tenofovir Disoproxil Fumarate, 15-75 µg/mL for Cobicistat and 15-75 µg/mL for Elvitegravir with correlation coefficients (r 2 =0.999). The percentage recoveries of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir were achieved in the range of 98-102 % which was within the acceptance criteria. The percentage RSD was NMT 2 % which proved the precision of the developed method. The developed method is simple, sensitive, rapid, linear, precise, rugged, accurate, specific, and robust. The forced degradation studies were performed by using HCl, NaOH, H 2 O 2 , thermal, UV radiation. Emtricitabine are more sensitive towards alkaline hydrolysis degradation condition, Tenofovir Disoproxil Fumarate is more sensitive towards oxidative degradation condition, Cobicistat are more sensitive towards alkaline hydrolysis degradation condition and Elvitegravir are more sensitive towards acidic hydrolysis degradation condition which was shown in Table 13 and 14. No interference from any components of pharmaceutical dosage form or degradation products was observed and the method has been successfully used to perform long term and accelerated stability studies of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir formulations. Hence it can be used for the hyphenated instrumental analysis of Emtricitabine, Tenofovir Disoproxil Fumarate, Cobicistat and Elvitegravir in their bulk and combine dosage form. 
